Sodelglitazar, formerly known as GW 677954, is a thiazole PPARδ receptor agonist developed by GlaxoSmithKline. While it is primarily active at the PPARδ receptor, it is considered a pan agonist with activity at PPARα and PPARγ receptors.
Safety Phase 2 studies were terminated prior to completion due to safety findings in rodent studies.
See also Elafibranor GW0742 GW501516 MBX-8025 Peroxisome proliferator-activated receptor
References